Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2023 1
2024 3
2025 4
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational study.
Inno A, Veccia A, D'Argento E, Morgillo F, Pizzutilo EG, Vitiello F, Pavan A, Lombardo F, Russano M, Sforza V, Colamartini F, Genova C, Chiari R, Cristofano A, Delconte A, Vattemi E, Dessi A, Galanti D, Busato S, Palazzolo G, Savastano C, Bianco A, Verderame F, Mazzi C, Marchetti F, Kinspergher S, Occhipinti D, Corte CMD, Piscazzi D, Gilli M, Bria E, Caffo O, Gori S. Inno A, et al. Among authors: occhipinti d. Cancer Immunol Immunother. 2025 Jul 12;74(8):266. doi: 10.1007/s00262-025-04125-w. Cancer Immunol Immunother. 2025. PMID: 40650694 Free PMC article.
Enhanced response to dabrafenib plus trametinib in a patient with BRAF V600E lung cancer harboring an RNF43 variant of unknown significance: a case report.
D'Argento E, Vitale A, Russo J, Minucci A, Cancellieri A, Stefani A, Monaca F, Horn G, Occhipinti D, Troisi P, Scala A, Polidori S, D'Argento F, Di Salvatore M, Bria E, Tortora G. D'Argento E, et al. Among authors: occhipinti d. Front Oncol. 2025 Jul 15;15:1600457. doi: 10.3389/fonc.2025.1600457. eCollection 2025. Front Oncol. 2025. PMID: 40735046 Free PMC article.
Pattern of disease recurrence and outcomes after progression of high-risk renal cell carcinoma (RCC) patients treated with adjuvant immunotherapy.
Ciccarese C, Occhipinti D, Arduini D, Di Leo D, Neri A, Roca L, Messina G, Troisi P, Pedone RR, Fucile MA, Belletto R, Sardaro V, Ligato C, Ajdhoni R, Caliciotti F, Sighinolfi C, Tagliaferri L, Rocco B, Tortora G, Iacovelli R. Ciccarese C, et al. Among authors: occhipinti d. Cancer Immunol Immunother. 2026 Feb 25;75(3):85. doi: 10.1007/s00262-026-04331-0. Cancer Immunol Immunother. 2026. PMID: 41739194 Free PMC article.
2024 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma.
Beccia V, Arduini D, Iacovelli R, Scala A, Occhipinti D, Ligato C, Roca L, Russo P, Foschi N, Tortora G, Ciccarese C. Beccia V, et al. Among authors: occhipinti d. Expert Rev Anticancer Ther. 2024 Aug;24(8):657-660. doi: 10.1080/14737140.2024.2370382. Epub 2024 Jun 27. Expert Rev Anticancer Ther. 2024. PMID: 38912860
Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK-positive advanced non-small cell lung cancer.
Vita E, Monaca F, Milardi D, Mastrantoni L, Stefani A, Vergani E, Russo J, Barone D, Sparagna I, Vitale A, Scala A, Occhipinti D, Di Salvatore M, Pontecorvi A, Tortora G, Bria E. Vita E, et al. Among authors: occhipinti d. Cancer. 2024 Aug 1;130(15):2611-2620. doi: 10.1002/cncr.35293. Epub 2024 Mar 28. Cancer. 2024. PMID: 38549441 Free article.
Clinical and technical insights on KIM-1: what we need to know.
Arduini D, Agostini A, Ciccarese C, Occhipinti D, Messina G, Pedone RR, Tortora G, Carbone C, Iacovelli R. Arduini D, et al. Among authors: occhipinti d. Minerva Urol Nephrol. 2026 Jan 19. doi: 10.23736/S2724-6051.25.06760-6. Online ahead of print. Minerva Urol Nephrol. 2026. PMID: 41553792 No abstract available.